Marcio Covas Moschovas, Attending Urologist at AdventHealth, shared a post on LinkedIn:
“Are we finally bridging the gap between tumor biology and clinical risk models in prostate cancer?
Please let me know your opinion on the comments below!
A new study from our group explores exactly that – integrating genomic data into traditional clinical tools to improve the prediction of biochemical recurrence after radical prostatectomy.
We developed two novel scores:
- CAPRA-G (preoperative)
- CAPRA-SG (postoperative)
By incorporating the Genomic Prostate Score (GPS) into established CAPRA frameworks, we significantly improved risk prediction.
Key insights:
Genomics adds independent prognostic value beyond clinical variables
Predictive accuracy improved meaningfully (C-index ↑ from 0.67 → 0.76 pre-op)
Better risk stratification, especially in the intermediate-risk population, where decision-making is most challenging
Provides a simple, clinically applicable tool translating complex biology into daily practice
- Why this matters: We are moving toward precision urology, where decisions are no longer based only on PSA, Gleason, or stage – but also on tumor biology.
- The challenge: Cost, accessibility, and need for external validation remain key barriers before widespread adoption.”
Title: Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy
Authors: Yu Ozawa, Marcio Covas Moschovas, Marco Sandri, Rohan Sharma, Marco Montesi, Saleh Bubishat, Shady Saikali, Maxwell Boger, Shannon Roof, Travis Rogers, Vipul Patel
Read the Full Article.
Other articles featuring Marcio Covas Moschovas on OncoDaily.